Limitations of the NMN-BBB score in capturing therapeutic accessibility

The Lancet Medical Imaging & Theranostics 2026 Open access

Read full text
Authors: Ali Nabavizadeh, Ramon Barajas, Derek Richard Johnson, Jana Ivanidze
DOI: 10.1016/j.lanmit.2026.100011
Cited by: 1
References: 5

Abstract

We read with interest the Personal View by Nathalie L Albert and colleagues proposing the Nuclear Medicine and Neuro-Oncology blood–brain barrier (NMN-BBB) score for imaging-based classification of BBB disruption in glioblastoma.1 The authors should be commended for highlighting the importance of heterogeneous BBB permeability in neuro-oncology trials and for proposing a pragmatic imaging-based framework for patient stratification. However, several conceptual and methodological limitations warrant discussion.

Fields of Study & Subjects

Glioma Diagnosis and Treatment MRI in cancer diagnosis Radiomics and Machine Learning in Medical Imaging

Publication details

Journal / source
The Lancet Medical Imaging & Theranostics
Publisher
Elsevier BV
Volume
1
Issue
1
Pages
100011–100011
Publication date
1 August 2026
Language
EN